Trials / Completed
CompletedNCT00322595
Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder
An International, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (Seroquel SR™ ) in the Treatment of Generalized Anxiety Disorder (SILVER)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 800 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the efficacy of (SEROQUEL SR™ ) quetiapine fumarate sustained-release (SR) compared to placebo in the treatment of anxiety symptoms in patients with generalized anxiety disorder (GAD). PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Quetiapine fumarate | |
| DRUG | Paroxetine |
Timeline
- Start date
- 2006-05-01
- Completion
- 2007-05-01
- First posted
- 2006-05-08
- Last updated
- 2008-12-22
Locations
86 sites across 15 countries: Argentina, Bulgaria, Canada, Czechia, Denmark, Finland, France, Germany, Mexico, Norway, Romania, Slovakia, South Africa, Spain, Sweden
Source: ClinicalTrials.gov record NCT00322595. Inclusion in this directory is not an endorsement.